236 related articles for article (PubMed ID: 10963601)
21. Syk protein-tyrosine kinase is involved in neuron-like differentiation of embryonal carcinoma P19 cells.
Tsujimura T; Yanagi S; Inatome R; Takano T; Ishihara I; Mitsui N; Takahashi S; Yamamura H
FEBS Lett; 2001 Feb; 489(2-3):129-33. PubMed ID: 11165236
[TBL] [Abstract][Full Text] [Related]
22. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).
Kuno Y; Abe A; Emi N; Iida M; Yokozawa T; Towatari M; Tanimoto M; Saito H
Blood; 2001 Feb; 97(4):1050-5. PubMed ID: 11159536
[TBL] [Abstract][Full Text] [Related]
23. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.
Luangdilok S; Box C; Patterson L; Court W; Harrington K; Pitkin L; Rhŷs-Evans P; O-charoenrat P; Eccles S
Cancer Res; 2007 Aug; 67(16):7907-16. PubMed ID: 17699797
[TBL] [Abstract][Full Text] [Related]
24. [Functions of spleen tyrosine kinase (Syk) gene and its correlation to neoplasms].
Wang HY; Zhang ZX
Ai Zheng; 2007 May; 26(5):555-60. PubMed ID: 17672952
[TBL] [Abstract][Full Text] [Related]
25. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells.
Hoeller C; Thallinger C; Pratscher B; Bister MD; Schicher N; Loewe R; Heere-Ress E; Roka F; Sexl V; Pehamberger H
J Invest Dermatol; 2005 Jun; 124(6):1293-9. PubMed ID: 15955106
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Chakraborty G; Rangaswami H; Jain S; Kundu GC
J Biol Chem; 2006 Apr; 281(16):11322-31. PubMed ID: 16474166
[TBL] [Abstract][Full Text] [Related]
27. Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB
Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717
[TBL] [Abstract][Full Text] [Related]
28. LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
Zhai Y; Wirth J; Kang S; Welsch CW; Esselman WJ
Mol Carcinog; 1995 Oct; 14(2):103-10. PubMed ID: 7576097
[TBL] [Abstract][Full Text] [Related]
29. [Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells].
Wang L; Hu Y; Yang ZL; Song XM; Wang JP
Ai Zheng; 2007 May; 26(5):469-72. PubMed ID: 17672934
[TBL] [Abstract][Full Text] [Related]
30. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy.
Navara CS
Curr Pharm Des; 2004; 10(15):1739-44. PubMed ID: 15180536
[TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders.
Ulanova M; Puttagunta L; Kim MK; Schreiber AD; Befus AD
Curr Opin Investig Drugs; 2003 May; 4(5):552-5. PubMed ID: 12833648
[TBL] [Abstract][Full Text] [Related]
32. Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Repana K; Papazisis K; Foukas P; Valeri R; Kortsaris A; Deligiorgi E; Kyriakidis D
Anticancer Res; 2006; 26(6C):4949-54. PubMed ID: 17214368
[TBL] [Abstract][Full Text] [Related]
33. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.
Zyss D; Montcourrier P; Vidal B; Anguille C; Mérezègue F; Sahuquet A; Mangeat PH; Coopman PJ
Cancer Res; 2005 Dec; 65(23):10872-80. PubMed ID: 16322234
[TBL] [Abstract][Full Text] [Related]
34. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer.
Dai JL; Wang L; Sahin AA; Broemeling LD; Schutte M; Pan Y
Oncogene; 2004 Nov; 23(53):8681-7. PubMed ID: 15467753
[TBL] [Abstract][Full Text] [Related]
35. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
[TBL] [Abstract][Full Text] [Related]
36. [Spleen tyrosine kinase (L) suppresses breast cancer development by downregulating the expression of cyclin D1, ID1, B-myb and Fra1].
Wang L; Wang JP; Song XM; He YL
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(2):85-9. PubMed ID: 17418011
[TBL] [Abstract][Full Text] [Related]
37. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Bailet O; Fenouille N; Abbe P; Robert G; Rocchi S; Gonthier N; Denoyelle C; Ticchioni M; Ortonne JP; Ballotti R; Deckert M; Tartare-Deckert S
Cancer Res; 2009 Apr; 69(7):2748-56. PubMed ID: 19293188
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity.
Zhang J; Kimura T; Siraganian RP
J Immunol; 1998 Oct; 161(8):4366-74. PubMed ID: 9780214
[TBL] [Abstract][Full Text] [Related]
39. Molecular biology and genetics of breast cancer development: a clinical perspective.
Buchholz TA; Wazer DE
Semin Radiat Oncol; 2002 Oct; 12(4):285-95. PubMed ID: 12382187
[TBL] [Abstract][Full Text] [Related]
40. Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis.
Kim MK; Pan XQ; Huang ZY; Hunter S; Hwang PH; Indik ZK; Schreiber AD
Clin Immunol; 2001 Jan; 98(1):125-32. PubMed ID: 11141335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
